lifestyle.cfxmagazine.com

Author: AbelZeta Pharma, Inc

AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca

January 18, 2026
ElpasBio and Fosun Kairos Announce Commercialization Collaboration for AlloJoin® Stem Cell Therapy

January 13, 2026
AbelZeta to Attend 44th Annual J.P. Morgan Healthcare Conference and Join Panel Discussion

January 6, 2026
AbelZeta Announces Late-Breaking Poster Presentation at ACR Convergence 2025 of First-in-Human Phase I Trial of anti-CD20/BCMA Bispecific CAR-T Therapy in Patients with Refractory Autoimmune Diseases

October 20, 2025